U.S. markets close in 50 minutes
  • S&P 500

    4,136.83
    -8.36 (-0.20%)
     
  • Dow 30

    32,817.94
    +14.47 (+0.04%)
     
  • Nasdaq

    12,625.02
    -32.54 (-0.26%)
     
  • Russell 2000

    1,934.44
    +12.62 (+0.66%)
     
  • Crude Oil

    90.43
    +1.42 (+1.60%)
     
  • Gold

    1,803.80
    +12.60 (+0.70%)
     
  • Silver

    20.60
    +0.76 (+3.82%)
     
  • EUR/USD

    1.0194
    +0.0006 (+0.06%)
     
  • 10-Yr Bond

    2.7700
    -0.0700 (-2.46%)
     
  • GBP/USD

    1.2076
    +0.0006 (+0.05%)
     
  • USD/JPY

    134.8600
    -0.1100 (-0.08%)
     
  • BTC-USD

    23,937.84
    +726.60 (+3.13%)
     
  • CMC Crypto 200

    558.03
    +15.16 (+2.79%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Annexon Biosciences
Annexon Biosciences

BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will participate in a virtual panel titled, “Orphan CNS Panel,” during the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, to bring therapies to patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company’s proprietary complement-targeting platform utilizes well-researched classical complement-mediated autoimmune and neurodegenerative processes triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a broad portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway, which may provide more complete protection against complement-mediated disorders of the body, brain and eye. The company’s pipeline includes three clinical-stage drug candidates, ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration), as well as a robust early-stage pipeline of preclinical and discovery stage programs. Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Investor Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:

Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com